Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 8/20 | 0.61 |
| ▸ | HTR1A | P08908 | 7/20 | 0.61 |
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | HTR7 | P34969 | 7/20 | 0.61 |
| ▸ | HTR6 | P50406 | 7/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | DRD5 | P21918 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033933 | 1.00 | CA9 (0.71) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL6324557 | 0.98 | CA9 (0.73) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL8973563 | 0.94 | CA9 (0.72) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL30872949 | 0.87 | CA12 (0.71) | CA9CA12CA2ELANE | |
| SCHEMBL9437884 | 0.87 | CA12 (0.71) | CA9CA12CA2ELANE | |
| SCHEMBL29621871 | 0.85 | CA9 (0.97) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL14560535 | 0.85 | CA9 (0.97) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL29739791 | 0.85 | CA9 (0.71) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL9826952 | 0.83 | CA9 (0.73) | CA9CA12HDAC1HDAC2CA2 | |
| SCHEMBL17329453 | 0.83 | CA9 (0.73) | CA9CA12HDAC1HDAC2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | CA9 4236/4885CA12 3272/4885HDAC1 1075/4885 |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | GALR1, GALNT1, GALK1 | CA9 3137/4885CA12 2849/4885HDAC1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.